Savanne Beekman
Rotterdam, ZH, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Assessment of quality control and effect of radiolysis on the in vivo biodistribution of [177Lu]Lu-PSMA-I&T.
Journal: EJNMMI radiopharmacy and chemistry
Published: October 03, 2025
Revolutionizing Solid Tumor Surgery with Fibroblast Activation Protein (FAP)-Targeted Imaging Probes for a Fluorescence-Guided Surgery of Pancreatic Cancer.
Journal: Bioconjugate chemistry
Published: October 01, 2025
Potentials and practical challenges of terbium-161 labeled radiopharmaceuticals.
Journal: EJNMMI radiopharmacy and chemistry
Published: June 17, 2025
eSOMA-DM1, a Maytansinoid-Based Theranostic Small-Molecule Drug Conjugate for Neuroendocrine Tumors.
eSOMA-DM1, a Maytansinoid-Based Theranostic Small-Molecule Drug Conjugate for Neuroendocrine Tumors.
Journal: Bioconjugate chemistry
Published: October 12, 2024
eTFC-01: a dual-labeled chelate-bridged tracer for SSTR2-positive tumors.
Journal: EJNMMI radiopharmacy and chemistry
Published: April 08, 2024
Synthesis and Evaluation of ePSMA-DM1: A New Theranostic Small-Molecule Drug Conjugate (T-SMDC) for Prostate Cancer.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: June 20, 2023
[212Pb]Pb-eSOMA-01: A Promising Radioligand for Targeted Alpha Therapy of Neuroendocrine Tumors.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: June 09, 2023
Radiochemical and Biological Evaluation of 3p-C-NETA-ePSMA-16, a Promising PSMA-Targeting Agent for Radiotheranostics.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: May 17, 2023
Preclinical Evaluation of a PSMA-Targeting Homodimer with an Optimized Linker for Imaging of Prostate Cancer.
Journal: Molecules (Basel, Switzerland)
Published: April 21, 2023
First preclinical evaluation of [225Ac]Ac-DOTA-JR11 and comparison with [177Lu]Lu-DOTA-JR11, alpha versus beta radionuclide therapy of NETs.
Journal: EJNMMI radiopharmacy and chemistry
Published: April 20, 2023
Synthesis and Evaluation of Two Long-Acting SSTR2 Antagonists for Radionuclide Therapy of Neuroendocrine Tumors.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: August 13, 2022
Showing 1-11 of 11
Last Updated: 09/26/2026